TABLE II.

Incidence of diarrhea with epidermal growth factor receptor tyrosine kinase inhibitors from selected clinical trials in non-small-cell lung cancer^a

Tyrosine kinase inhibitor	Grade (%) of diarrhea
	All	≥3
Erlotinib 150 mg
All studies	10–69	0–17
Phase iii studies	18–68	1–12
Gefitinib 250 mg and 500 mg
All studies	27–75	0–25
250 mg	27–58	0–10
500 mg	51–75	5–25
Phase iii studies	27–69	1–25
250 mg	27–58	1–10
500 mg	51–69	12–25
Afatinib 40 mg and 50 mg
All studies	67–100	0–37
40 mg	67–97	0–14
50 mg	87–100	17–37
Phase iii studies	87–95	5–17
40 mg	88–95	5–14
50 mg	87	17
Dacomitinib 15 mg, 30 mg, and 45 mg
All studies (phase ii)	77–97	0–15
30 mg	77	0
45 mg	81–97	13–15

^aAdapted and updated from Hirsh 2011^{8–12,30–66}.